Dipexium Pharmaceuticals (DPRX) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Dipexium Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 13, 2015 7:00 AM EDTNEW YORK, Aug. 13, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.Â
"We made significant progress in all areas of our business in the second quarter," said David P. Luci, President and CEO of Dipexium Pharmaceuticals. "Most notably, we received guidance from the European Medicines Agency regarding Locilex's European clinical and regulatory pathway. In addition, we completed our secondary public offering of common... More
